A team from Finland and the USA investigated the association of Helicobacter pylori carriage and the incidence of pancreatic cancer.
A cohort of 29,133 male Finnish smokers, aged 50-69 years, was included in the nested case-control study.
Of these, 121 individuals with pancreatic cancer were identified.
226 control subjects were matched on date of baseline serum collection, study center, age, trial intervention, and completion of the dietary questionnaire.
All controls were alive at the time the matching case subject was diagnosed and remained free of cancer during up to 10 years of follow-up.
|Subjects with H. pylori were twice as likely to have pancreatic cancer.
|Journal of the National Cancer Institute|
The researchers measured levels of immunoglobulin G antibodies to whole-cell H. pylori. In addition, CagA+ antigens from stored baseline serum were measured by enzyme-linked immunosorbent assay.
Smoking-adjusted odds ratios (ORs) were estimated by use of conditional logistic regression. The statistical tests were two-sided.
Seroprevalence of H. pylori was found to be 82% and 73% among case and control subjects, respectively.
The researchers found that, compared with seronegative subjects, those with H. pylori or CagA+ strains were at statistically significantly elevated risk of pancreatic cancer (OR = 1.87 and 2.01, respectively).
Dr Rachael Z. Stolzenberg-Solomon, of the National Institutes of Health, Bethesda, Maryland, concluded on behalf of her colleagues, "Our findings support a possible role for H. pylori carriage in the development of exocrine pancreatic cancer."